Lineage Cell Therapeutics (LCTX) Balance Sheet: Assets & Liabilities

Lineage Cell Therapeutics (LCTX) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Lineage Cell Therapeutics reported total assets of $112.58M and total liabilities of $69.24M. Shareholders' equity was $44.55M, down 42.2% from $77.01M a year earlier. Total debt stood at $2.42M against $55.78M in cash and short-term investments, a net cash position of $53.36M. That puts debt-to-equity at 0.05, compared with 0.03 a year earlier.

Lineage Cell Therapeutics Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Lineage Cell Therapeutics, Inc. (LCTX) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Current Assets
Cash and Cash Equivalents	40.79	45.79	35.44	11.36	55.74	32.59	9.50	23.59	36.84
Short-Term Investments	14.99	2.02	0.05	46.52	2.62	8.98	21.22	7.15	1.34
Cash & Short-Term Investments	55.78	47.81	35.49	57.88	58.36	41.56	30.72	30.74	38.18
Accounts Receivable	1.56	0.64	0.75	0.30	50.84	0.00	24.74	3.72	3.05
Inventory	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Current Assets	1.81	2.55	2.20	1.83	2.35	2.43	2.06	1.90	1.40
Total Current Assets	59.16	51.00	38.44	60.00	111.55	44.00	57.52	36.36	42.62
Non-Current Assets
Property, Plant & Equipment (Net)	4.70	4.40	4.77	5.67	4.87	5.63	8.18	5.84	5.53
Long-Term Investments	0.00	0.00	0.00	0.58	0.00	0.00	0.10	33.73	117.17
Goodwill	10.67	10.67	10.67	10.67	10.67	10.67	10.67	0.00	0.00
Intangible Assets	31.70	46.54	46.56	46.69	46.82	47.03	48.25	3.13	6.90
Other Non-Current Assets	0.56	0.61	0.58	0.63	0.63	0.62	0.76	0.51	1.02
Total Non-Current Assets	53.43	62.22	62.58	63.66	63.00	63.95	67.96	65.30	130.62
Total Assets	112.58	113.22	101.02	123.66	174.55	107.95	125.48	101.66	173.24
Current Liabilities
Accounts Payable	2.34	5.44	2.05	2.39	27.97	2.61	2.43	2.36	0.94
Short-Term Debt	0.85	1.15	0.88	0.95	0.83	1.29	1.22	0.31	0.36
Accrued Liabilities	1.10	4.26	1.10	3.83	24.25	3.67	-	-	-
Deferred Revenue	3.33	7.39	10.81	9.42	18.12	0.19	0.05	0.04	0.80
Other Current Liabilities	4.84	4.26	4.22	6.22	0.20	3.68	2.80	4.10	4.78
Total Current Liabilities	11.37	13.98	17.96	18.98	47.12	7.77	6.49	6.81	6.88
Non-Current Liabilities
Long-Term Debt	1.57	1.36	2.07	2.94	1.97	2.54	3.95	1.96	1.17
Deferred Tax Liabilities	0.02	0.27	0.27	2.08	2.08	2.08	3.32	0.00	0.00
Other Non-Current Liabilities	43.91	20.87	0.00	0.00	34.56	0.44	0.28	0.64	0.93
Total Non-Current Liabilities	57.87	22.23	21.04	32.75	36.53	5.05	7.74	2.60	2.10
Total Liabilities	69.24	36.21	39.00	51.73	83.65	12.82	14.23	9.41	8.98
Stockholders' Equity
Common Stock	515.47	484.72	451.34	440.28	434.53	393.94	387.06	354.27	378.49
Retained Earnings	-467.00	-403.47	-384.86	-363.37	-337.10	-294.08	-273.42	-261.86	-216.30
Accumulated Other Comprehensive Income	-3.92	-2.88	-3.07	-3.57	-5.21	-3.67	-0.68	1.43	0.45
Minority Interest	-1.20	-1.37	-1.40	-1.40	-1.32	-1.07	-1.71	-1.59	1.62
Shares Outstanding	243.12	220.42	174.99	170.09	169.48	-	-	-	-
Total Stockholders' Equity	44.55	77.01	63.42	73.34	90.90	96.20	112.96	93.84	162.64
Total Liabilities & Equity	112.58	113.22	101.02	123.66	174.55	107.95	125.48	101.66	173.24

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Lineage Cell Therapeutics Balance Sheet

How much debt does Lineage Cell Therapeutics have?

Lineage Cell Therapeutics had total debt of $2.42M as of Dec 31, 2025, against $55.78M in cash and short-term investments. Its debt-to-equity ratio was 0.05. Total debt was $2.51M a year earlier.

What are Lineage Cell Therapeutics's total assets?

Lineage Cell Therapeutics reported total assets of $112.58M as of Dec 31, 2025, down 0.6% from $113.22M a year earlier. Total liabilities were $69.24M.

What is Lineage Cell Therapeutics's shareholders' equity?

Lineage Cell Therapeutics's shareholders' equity was $44.55M as of Dec 31, 2025, or about $0.18 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition